Introduction
============

Diabetes is a major cause of morbidity, disability, and mortality, affecting over 27 million persons in the United States.[@b1-jmdh-7-533] The World Health Organization has predicted a global increase in diabetes prevalence of 39% between the years 2000 and 2030, reflecting an increase of 366 million people by the year 2030.[@b2-jmdh-7-533] In the United States, in 2007, the cost of diabetes was \$174 billion, roughly 10% of total health care expenditures[@b3-jmdh-7-533] and by 2030, health care spending on diabetes is projected to reach \$860 billion.[@b4-jmdh-7-533] An enormous opportunity for quality improvement and cost reduction lies within identifying pragmatic interventions that are effective in the management of diabetes, yet, are sustainable and create value from the point of view of the patient, clinician, and delivery system.

Intermountain Healthcare (IH) is a not-for-profit integrated delivery system in Utah and Idaho that has a network of 22 hospitals and 185 clinics providing more than half of all health care delivered in the region.[@b5-jmdh-7-533] Since 2010, primary care practices have focused on improving the management of diabetes by implementing best-practice guidelines, benchmarking against other health care institutions, and reporting adherence to an all-or-none five elements diabetes bundle ([Table 1](#t1-jmdh-7-533){ref-type="table"}). The IH diabetes bundle is an internal measurement tool to gauge intermediate quality outcomes associated with diabetes. It was previously developed by an internal group of physician experts who thoroughly reviewed and considered the evidence. Bundle components were chosen if they were clinically meaningful and if they were indicators of quality care for patients with diabetes. Data systems were created to support measurement over time. The physician expert panel vetted the bundle components with medical and operational leadership, began collecting data to benchmark success, and developed a clinical board goal to make targeted improvements over the last 2 years. The IH diabetes bundle is an all-or-none measurement and requires a patient to meet all five parts of the bundle within the last 12 months of care, except for a retinal eye exam which may be completed within the last 2 years. Meeting the diabetes bundle is one component of IH's 2013 primary care pay for performance incentive program.

Another strategy within IH clinics has been the deployment of team-based care via its mental health integration (MHI)[@b6-jmdh-7-533] -- integration of mental health into primary care -- and personalized primary care (PPC) -- IH's version of the national Patient-Centered Medical Home project. Both strategies have had a significant impact on improving patients' outcomes for diabetes especially with achievement of the diabetes bundle and lowering HbA~1c~, and are scheduled to be fully implemented across the system by early 2014.[@b7-jmdh-7-533]

Management strategies for diabetes have evolved to not only include appropriate medications, but also include guidelines that recommend diet, physical activity, and weight counseling.[@b8-jmdh-7-533]--[@b10-jmdh-7-533] The effectiveness of diabetes education has been well-established by clinical trials to demonstrate a beneficial effect on HbA~1c~ control, reduce complications and acute healthcare utilization, and subsequently, produce a reduction in the total cost of care to treat a diabetic patient.[@b11-jmdh-7-533]--[@b16-jmdh-7-533] However, there is little evidence with respect to the effect of diabetes education on improved outcomes as assessed by a "diabetes bundle", where multiple aspects of diabetes care and process outcomes are rolled up into one measure. Diabetes self-management education (DSME) has emerged as a strategy to educate, engage, and empower patients to achieve control of their diabetes; reducing health care utilization and cost, while improving outcomes. To test the hypothesis that DSME is associated with improvements in both processes and outcomes of diabetes care, a retrospective study was performed utilizing patients found within the IH's diabetes registry.

Methods
=======

A retrospective case-control study was conducted to evaluate the difference in IH five part diabetes bundle measure in patients who received DSME as compared to a control population from the same IH primary care practice who did not receive DSME during a similar time period. The primary outcome in this study was change in IH five part diabetes bundle measure performance before and after DSME. In addition, we evaluated the relationship between DSME and HbA~1c~ over time and the percentage of patients who had a decline in HbA~1c~ over time.

Study population
----------------

IH's Enterprise Data Warehouse (EDW) was queried for all adult type 2 diabetes mellitus patients (18--75 years of age) between 2011--2012 who received DSME from one of five American Diabetes Association (ADA)-certified diabetes education centers housed within the IH delivery system, and who had an HbA~1c~ measurement within 0--3 months before and 2--6 months after their first DSME visit. Patients meeting these criteria were further delineated for study if: 1) they met the national Healthcare Effectiveness Data and Information Set definition for inclusion in the IH diabetes registry;[@b17-jmdh-7-533] 2) their main provider was a primary care provider within the IH medical group; and 3) they had a baseline HbA~1c~ of 6.0%--14.0%. Similarly, a control population who did not receive DSME was selected from within the EDW system who met the criteria above during the same time period and from the same clinics that a case-patient was attributed to. Patients with missing clinical data (ie, diabetes bundle or HbA~1c~ measures) were excluded from the study. The study population was limited to patients whose main provider was a primary care physician employed by the medical group due to inconsistent data capture among affiliate practices and strong institutional support for primary care physicians who have been actively focused on improving the management of patients with diabetes. We eliminated all patients who had a baseline HbA~1c~ \>14% because these outliers may be artifact of miscoded data or extreme instances of poor diabetes control. Because the control population available was much larger than the study population, a random number generator was utilized to randomly select patients within this group. It was determined a priori that a 1:4 ratio of cases to controls matched by baseline HbA~1c~ category (6%--6.9%; 7%--7.9%; 8%--8.9% and ≥9.0%) would be appropriate to detect a difference in an all-or-none bundle of diabetes measures over time assuming a power of 80% and an alpha of 0.05. This study was approved by the IH institutional review board.

Diabetes education curriculum
-----------------------------

DSME provided to study participants was patterned after the American Dietetic Association/Morrison Health Care protocols for type 1 and type 2 diabetes mellitus and was consistent with the requirements from the National Standards for DSME.[@b17-jmdh-7-533],[@b18-jmdh-7-533] Participants can receive either 1 hour of individual or 2 hours of group training dependent on patient preference for coaching, however, total education cannot exceed 10 total hours of instruction within a 12 month period. All education was provided by certified diabetes educators (CDE) who in addition are either a registered nurse or dietitian. Patients received instruction in: self-monitoring of glucose levels; diet/exercise education; medication management specifically for insulin dependent participants; motivation for self-management; diabetes related problem solving, and lifestyle changes to help reduce the risks and complications of diabetes. In addition, goal-setting was incorporated into the DSME to increase the patient's knowledge about the disease and how they can achieve control over their own health. These goals were specific (eg, exercise three times per week, consume 60 g carbohydrate per meal) and established by the patients in conjunction with the CDE. The overall intent of DSME is to provide patients with knowledge, skill, and ability to manage their disease, support informed decision making, self-care behaviors, problem-solving, and active collaboration with the health care team, and to improve clinical outcomes, health status, and quality of life.[@b19-jmdh-7-533]

Study measurement
-----------------

### Baseline characteristics

As determined by billing codes, DSME patients were compared to non-DSME patients to assess whether differences in patient and clinic characteristics existed prior to the education visit and subsequent training. Baseline demographics included age, sex, race/ethnicity, and payer status. Education level for patients was not available. Clinical characteristics for the study cohort included chronic conditions such as heart failure, myocardial infarction, pulmonary disease, renal disease, Charlson comorbidity index[@b19-jmdh-7-533] (proxy marker for number of chronic conditions), and duration of diabetes history. Medication history for patients was incomplete and as such, was not included. Likewise, contextual clinic characteristics were collected for study patients including the type of primary care provider and the existence of team-based care programs such as PPC and MHI. Patients were assigned to a clinic through an imputation logic relying first on patient documentation as to their primary care provider. Secondarily, if a primary care provider was not identified, then the provider the patient has seen the most in the last 3 years.

### Study endpoints

Change in the five part diabetes bundle measure score was the primary outcome of interest. For patients who participated in DSME training, HbA~1c~ levels were analyzed within 3 months prior and 2--6 months after first visit with a CDE occurred. For control patients, the first and last HbA~1c~ values within the study period were utilized with at least 90--180 days between the tests. To be coded as adherent to the five part diabetes bundle, patients are required to have met all elements of the bundle based on the thresholds listed in [Table 1](#t1-jmdh-7-533){ref-type="table"}.

Statistical analysis
--------------------

Summary statistics were computed using frequencies and proportions for categorical variables which included means, medians, standard deviations, and ranges to describe the study population and clinic characteristics. Change in all-or-none bundle achievement rate was evaluated using a chi-square analysis to test the null hypothesis that there was no difference in the proportion of patients who met the all-or-none bundle before and after DSME. Change in HbA~1c~ levels between control and DSME cohorts were compared using a Student's *t*-test testing the null hypothesis that mean change scores were not different between the two groups. We also tested the effect of time by computing the difference in means at baseline and follow-up for each group to determine if there was a statistical difference in HbA~1c~ over time. Logistic regression was performed to determine the odds of an improvement in the diabetes bundle and HbA~1c~ decrease after DSME visit. Multivariable models were used to adjust for demographic (age, sex) characteristics, baseline HbA~1c~ %, Charlson comorbidity index, duration of diabetes, and also clinic characteristics such as PPC or MHI programs that were determined to be possible confounders of achieving our hypothesis. Covariate adjustment was selected based on variables that were clinically meaningful confounders rather than statistically significant predictors of the study outcomes. To avoid multicollinearity, diagnostic testing was employed using graphical and numerical techniques within each model. For these analyses, a *P*-value ≤0.05 was considered nominally statistically significant. All data were analyzed using Stata 12.0 (StataCorp LP, College Station, TX, USA).

Results
=======

As documented in [Figure 1](#f1-jmdh-7-533){ref-type="fig"}, we identified 7,957 adults with diabetes from our internal diabetes registry during the study period. Of these, 1,287 patients were excluded based on HbA~1c~ values less than 6% or greater than 14%. Another 1,949 patients were excluded due to having a primary care provider who was not employed by Intermountain Medical Group. Of those remaining (n=4,587), 384 subjects (9.0%) received DSME training. These case-patients were matched randomly at a 1:4 ratio with subjects with similar baseline HbA~1c~ values (n=1,536) who served as the control group.

Baseline demographic and clinical characteristics are summarized in [Table 2](#t2-jmdh-7-533){ref-type="table"}. Over half (52.79%) of the DSME group were female as compared to 47.9% in the control group (*P*=0.10). Patients receiving DSME training tended to be younger than control patients (56.8 years versus 59.4 years; *P*=0.002). There was no significant difference in insurance provider (*P*=0.35) among the two groups, with over half of the payer mix being commercial providers. There was no difference in race/ethnicity, with the majority of patients in both groups being of Caucasian descent.

Patients with DSME tended to have more pulmonary disease (*P*=0.02), less myocardial infarction prevalence (*P*=0.02), and trended toward more renal disease (*P*=0.07) as compared to patients in the control cohort. Yet, there was no difference in the prevalence of heart failure (14.10% versus 14.90%, *P*=0.676), or Charlson comorbidity index score (4.60 versus 4.50; *P*=0.46), a proxy marker for the number of chronic conditions a patient may have. Of note, patients with DSME tended to having shorter history of their diabetic disease with over 53% having a history of diabetes for less than 4 years as compared to 39% for patients in the control group (*P*\<0.0001).

[Table 3](#t3-jmdh-7-533){ref-type="table"} demonstrates that there was no significant difference among specialty type of primary care provider, with the majority of care falling within family medicine and internal medicine providers for case and control cohorts (94.70% versus 95.80%; *P*=0.56) respectively. Of the clinics where our DSME cohort received care, 92.71% had the PPC program as compared to 71.48% for the control cohort (\<0.001). Of note, fewer clinics where case patients received care typically had MHI programs (86.46%) as compared to the clinics attributed to patients without DSME (90.30%) (*P*=0.03).

[Figure 2A](#f2-jmdh-7-533){ref-type="fig"} demonstrates that the diabetes bundle performance in patients in the DSME group was significantly improved over time when baseline and follow-up periods were compared. While there was no difference in baseline compliance among the two groups (14.58% compared to 12.43%), there was a significant difference when measured at follow-up (32.03% compared to 23.05%) and the magnitude of improvement (17.45% versus 10.62%) was also highly significant (*P*\<0.0001). Similar results over time were seen for the difference in HbA~1c~ ([Figure 2B](#f2-jmdh-7-533){ref-type="fig"}). While there was no difference in baseline HbA~1c~ values among the two groups (8.58% to 7.77%), the magnitude of improvement in the DSME group was significantly greater than in the control group with the difference being 1.36% versus 0.81% (*P*\<0.0001) respectively ([Table 4](#t4-jmdh-7-533){ref-type="table"}). When one considers that a 1% decline in HbA~1c~ is associated with a 15% reduction in the risk of cardiovascular disease, these relatively small changes in HbA~1c~ translate to a clinically significant risk reduction for patients.[@b20-jmdh-7-533]

The odds of achieving an improvement in bundle achievement over time were greater for patients with DSME, with almost a 1.5 fold difference as compared to those without education. Multivariate modeling displayed in [Figure 3A and B](#f3-jmdh-7-533){ref-type="fig"}, demonstrate that even after adjusting for confounders such as age, sex, baseline HbA1c %, duration of diabetes disease, Charlson comorbidity index, and clinic characteristics (existence of PPC and MHI programs within the clinics) patients with DSME had a subsequent significant increase in their achievement to the five part diabetes bundle (odds ratio \[OR\] =1.49; confidence interval \[CI\] =1.11, 2.001; *P*\<0.008) as well as improvement in their HbA1c % (OR =2.80; CI =2.05, 3.83; *P*\<0.0001) as compared to those without DSME.

Discussion
==========

Management of patients with complex disease is one cornerstone of delaying and preventing complications and thus improving delivery of medical care, clinical outcomes, and appropriate utilization of health care resources. Although published evidence-based guidelines exist, care often fails to meet these guidelines due to barriers such as lack of time during office visits, patient adherence, and the struggle to stay current with new information and to recall specific instructions that are relevant to each patient. After previously re-designing their approach to managing patients with diabetes which includes a nine part all-or-none diabetes bundle, Geisinger Health System has demonstrated improvement not only in process measures and overall adherence to the bundle, but also clinical metrics such as HbA~1c~ \<7%, LDL \<100 mg/dL, and blood pressure \<130/80 mmHg that have proven to be effective downstream in the management of diabetic complications.[@b21-jmdh-7-533],[@b22-jmdh-7-533] With over 146 distinct measures in diabetes care and differing results-based distinct combinations and organizations,[@b21-jmdh-7-533] IH employs a five part bundle as an internal measurement tool to gauge intermediate quality outcomes associated with diabetes. Care that is more consistent and reliable has become a measure of how well we have been able to manage patients with diabetes, allowing for comparison to occur across clinics and providers at IH and with other groups nationally, leading to a more coordinated and accountable team-based care strategy. Finding innovative ways to improve the rate of bundle compliance has become the focal point of operational and clinical leadership at IH and our findings suggest that DSME can help achieve this, consistent with IH's efforts to reduce variability in care and improve consistent application of evidence-based medicine.

While a large body of literature supports the effectiveness of DSME in improving diabetes outcomes,[@b23-jmdh-7-533]--[@b25-jmdh-7-533] much less evidence exists as to whether DSME could improve achievement of a five part diabetes bundle, a metric that has been created from evidence-based guidelines known to improve outcomes associated with diabetes complications. The findings of this study clearly support previous studies on improvement of HbA~1c~ levels with diabetes education beyond standard treatment alone, yet, also contribute to the limited body of knowledge surrounding methods to improve upon bundle achievement.[@b11-jmdh-7-533],[@b25-jmdh-7-533],[@b26-jmdh-7-533] The same literature also supports the cost benefit of DSME. An economic analysis conducted in 2000 by Klonoff and Schwartz reported that for every US \$1 spent on DSME, there was a net saving of \$0.44 to \$8.76.[@b27-jmdh-7-533] In a systematic review conducted by Boren et al, 18 of 26 papers reported findings associating diabetes education (and disease management) with decreased costs, cost savings, cost effectiveness, or positive return on investment.[@b14-jmdh-7-533] A study by Duncan et al also published in 2009, documented that commercially insured members who receive diabetes education cost, on average, 5.7% less than members who do not participate in diabetes education and participating Medicare members cost significantly less (14%).[@b16-jmdh-7-533] While DSME has been shown to be cost effective, results from a previously unpublished IH study showed that patients who meet all five components of the IH diabetes bundle may be less costly, even for those with multiple comorbidities.

While this study confirms the impact of DSME on improving HbA~1c~ it also demonstrates that patients receiving DSME within an ADA center are 1.5 times more likely to improve their five part diabetes bundle score within 6 months. This is an important and novel finding since improving bundle achievement tends to have an even greater clinical benefit to the patients and more efficiency in practice than just improving one key marker for diabetes such as HbA~1c~.[@b27-jmdh-7-533] Each component of the bundle affects patient outcomes and potential complications a patient with diabetes may experience. Tracking multiple components through a bundle compliance rate is a unique opportunity for the clinical team to focus on multiple measures that when assessed together, address the holistic complexity of this disease.

It should be noted that while DSME increases adherence to the bundle, we also found that patients managed in clinics with MHI attained higher rates of bundle achievement compared to patients who did not have access to this resource. This is likely the result of team-based care focusing on mental health and wellness which may help diabetic patients to become more compliant with their overall treatment regimen; as well as improving awareness within the clinical team to be more in-tune with the broader needs of their patients.[@b7-jmdh-7-533] Since the Diabetes Attitudes Wishes and Needs 2 (DAWN2) study reported that psychosocial support is both critical and often inadequate with current DSME programs, the finding that MHI results in higher rates of bundle achievement merits further investigation.[@b28-jmdh-7-533]

Limitations
===========

While the methodology used in this study attempted to account for practice variation across the IH clinics where the patients received treatment for their diabetes, it might not account for all variation in practice which could affect the observed results. While we noted the impact of the MHI program on improving bundle compliance, this merits further study which is in progress. This study was a nested case-control study of patients identified within the IH diabetes registry and may not be sufficiently representative of all patients who had received DSME. The control group was carefully selected to make it comparable to the study group, but there may be inherent unaccounted differences that still remain which could affect the results observed. Since the IH diabetes registry does not distinguish between type 1 or type 2 diabetes mellitus, our study population may still include both types of the disease even though we limited our provider population to only primary care providers and did not consider those who delivered specialty care such as endocrinologists or diabetologists. In addition, we did not adjust for history or adherence to medication as this information was not consistently available for all patients. Similarly, we did not adjust for education levels between the two groups as this information was not available within our EDW. It should also be acknowledged that the study population was largely Caucasian and therefore, these results need to be evaluated with more ethnically diverse populations. Finally, outcomes of interest were only evaluated within 6 months of a DSME visit and longitudinal evaluation is warranted.

Conclusion
==========

In summary, this study supports the existing literature on the effectiveness of DSME programs, and demonstrates that an ADA accredited DSME program at IH improves HbA~1c~ levels beyond standard care treatment for diabetes. More importantly, this study found that the DSME program significantly improved achievement of the five part diabetes bundle score, implying better overall outcomes for diabetic patients. Since many Patient Centered Medical Home demonstration projects are measuring improvement for diabetes on composite or bundle measures, including DSME as part of a Patient Centered Medical Home program seems to be an important strategy.[@b29-jmdh-7-533]

In the future landscape of health care delivery, many health care systems will be at full financial risk for patients, receiving a per member per month payment to cover all expenditures. It is imperative that we seek the triple aim of improved health care delivery, enhanced patient outcomes, at the lowest appropriate cost. Future study is needed to evaluate the impact on resources and medical costs associated with the improvement on the bundle achievement for patients who receive DSME.
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![Flow diagram.\
**Abbreviation:** DSME, diabetes self-management education.](jmdh-7-533Fig1){#f1-jmdh-7-533}

![Primary study outcomes.\
**Notes:** (**A**) Showing change in five part bundle (%) for patients with and without diabetes education. (**B**) Showing change in HbA~1c~ for patients with and without diabetes education.](jmdh-7-533Fig2){#f2-jmdh-7-533}

![Odds ratios.\
**Notes:** (**A**) Odds of DSME associated with an improvement in bundle adherence. (**B**) Odds of DSME associated with a decrease in HbA~1c~. \*Statistically significant: *P*\<0.001.\
**Abbreviation:** DSME, diabetes self-management education.](jmdh-7-533Fig3){#f3-jmdh-7-533}

###### 

Intermountain Healthcare's diabetes bundle definition

  Diabetes bundle elements
  -----------------------------------------------------------------------------------------------
  HbA~1c~ \<8.0%
  LDL-c \<100 mg/dL
  Retinal eye exam performed in the last 2 years
  Nephropathy screening through microalbumin testing or be prescribed an ACEi or ARB medication
  Documented blood pressure that is less than 140/90 mmHg

**Abbreviations:** ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor.

###### 

Baseline demographics of study population

                                      Diabetic education group, n=384 Mean/SD or %   No diabetic education group, n=1,536 Mean/SD or %   *P*-value
  ----------------------------------- ---------------------------------------------- --------------------------------------------------- -----------
  Female, %                           52.8                                           47.9                                                0.095
  Age at study start, years           56.8±14.1                                      59.4±14.3                                           0.0017
  Insurance, %                                                                                                                           
   Commercial                         50.9                                           54.4                                                0.351
   Medicare                           38.0                                           37.8                                                
   Medicaid                           5.9                                            5.0                                                 
   Self-pay                           5.01                                           2.9                                                 
  Race, %                                                                                                                                
   Caucasian (includes Hispanics)     89.06                                          84.70                                               0.292
   Black                              0.78                                           1.11                                                
   Asian                              1.56                                           2.34                                                
   Pacific Islander/Native American   1.56                                           2.60                                                
   Other                              7.03                                           9.24                                                
  Heart failure, %                    14.1                                           14.9                                                0.676
  Pulmonary disease, %                45.1                                           38.6                                                0.021
  Myocardial infarction, %            6.77                                           10.80                                               0.018
  Renal disease, %                    15.61                                          12.17                                               0.071
  Charlson comorbidity index          4.60±2.91                                      4.50±2.56                                           0.461
  History of diabetes, %                                                                                                                 
   \<1 years                          1.82                                           2.80                                                \<0.0001
   1--4 years                         52.08                                          37.24                                               
   5--9 years                         20.83                                          27.02                                               
   ≥10 years                          25.26                                          32.94                                               

**Abbreviation:** SD, standard deviation.

###### 

Clinic characteristics: study patients are attributed to provider/clinic

                                          Diabetic education group, n=384 Mean/SD or %   No diabetic education group, n=536 Mean/SD or %   *P*-value
  --------------------------------------- ---------------------------------------------- ------------------------------------------------- -----------
  Type of attributed provider, %                                                                                                           
   Family medicine                        56.51                                          57.0                                              0.556
   Internal medicine                      38.28                                          38.8                                              
   Geriatric                              0.0                                            0.52                                              
   Nurse practitioner                     3.64                                           2.41                                              
   Other                                  1.56                                           1.30                                              
  Mental health integration (% clinics)                                                                                                    
   Yes                                    86.46                                          90.30                                             0.03
   No                                     13.54                                          9.70                                              
  Personalized primary care (% clinics)                                                                                                    
   Yes                                    92.71                                          71.48                                             \<0.001
   No                                     7.29                                           28.52                                             

**Abbreviation:** SD, standard deviation.

###### 

Primary study outcomes

                                                          Diabetic education group, n=384 Mean/SD or %   No diabetic education group n=536 Mean/SD or %   *P*-value[a](#tfn4-jmdh-7-533){ref-type="table-fn"}
  ------------------------------------------------------- ---------------------------------------------- ------------------------------------------------ -----------------------------------------------------
  HbA~1c~, %                                                                                                                                              
   Baseline                                               8.69±1.94                                      8.58±1.82                                        0.28
   Follow-up                                              7.33±1.39                                      7.77±1.64                                        \<0.0001
   Difference[b](#tfn5-jmdh-7-533){ref-type="table-fn"}   −1.36±1.81                                     −0.81±1.71                                       \<0.0001
   *P*-value[c](#tfn6-jmdh-7-533){ref-type="table-fn"}    \<0.0001                                       \<0.0001                                         
  Five part diabetes bundle, % of adherent patients                                                                                                       
   Pre-study period                                       14.58                                          12.43                                            0.261
   Post-study period                                      32.03                                          23.05                                            \<0.0001
   *P*-value[c](#tfn6-jmdh-7-533){ref-type="table-fn"}    \<0.0001                                       \<0.0001                                         

**Notes:**

Comparison between groups

baseline to follow-up

comparison over time.

**Abbreviation:** SD, standard deviation.

[^1]: \*Joint first authors
